The large European study suggests the technique may be viable but also has a stiff learning curve and can result in a "wide spectrum" of complications.
April 19, 2021
Observational data from Switzerland add support to the idea that age shouldn’t be a barrier to TAVI, researchers say. While nonagenarian patients in the SwissTAVI Registry had a higher mortality risk compared with younger TAVI patients, these individuals were no more likely to die than people of similar age in the general population.
The question of how well the very elderly fare after TAVI is of increasing importance as the global population ages. By 2050, there will be around 76.7 million people older than 90 years, many of whom will develop aortic stenosis and face the choice of whether to undergo an invasive procedure.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Abbott’s XIENCE™ Stent Receives European Approval for One-Month Dual Anti-Platelet Therapy (DAPT) for High Bleeding Risk Patients
April 6, 2021 GMT
ABBOTT PARK, Ill., April 6, 2021 /PRNewswire/ Abbott (NYSE: ABT) today announced its XIENCE stent has received CE Mark in Europe for shorter duration of dual anti-platelet therapy (DAPT) – as short as 28 days, the shortest indication available in the world – for patients with high bleeding risk (HBR). The approval follows recent results from two studies that demonstrated both one-month or three-month DAPT followed by aspirin monotherapy is safe in HBR patients and is intended to improve patient outcomes and provide physicians more options to treat their patients. XIENCE is the most widely used stent worldwide and is the only stent to have evidence and data for both one-month and three-months DAPT followed by two different types of bloo